THE PHARMACOLOGY OF PRAZOSIN, A NOVEL ANTIHYPERTENSIVE AGENT

[1] DIFFERENT ALPHA-ADRENORECEPTORS IN CENTRAL NERVOUS-SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF CLONIDINE AND RECEPTOR BLOCKING-AGENTS [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1976, 292 (01) : 43 - 52

[2] ANDEN NE, 1978, NAUNYNSCHMIEDEBERGS, V302, P294

[3] ANDERSON MJ, 1979, BRIT J PHARMACOL, V66, pP151

[4] PRAZOSIN IN HYPERTENSION WITH HEART-FAILURE [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1979, 1 (06) : S56 - S62

[5] ALPHA-ADRENERGIC BLOCKING ACTIVITY OF PRAZOSIN - EFFECT ON CATECHOLAMINE LEVELS AND CATECHOLAMINE SYNTHETIC ENZYMES [J]. BIOCHEMICAL PHARMACOLOGY, 1979, 28 (07) : 1233 - 1237

[6] EFFICACY OF AMBULATORY SYSTEMIC VASODILATOR THERAPY WITH ORAL PRAZOSIN IN CHRONIC REFRACTORY HEART-FAILURE - CONCOMITANT RELIEF OF PULMONARY CONGESTION AND ELEVATION OF PUMP OUTPUT DEMONSTRATED BY IMPROVEMENTS IN SYMPTOMATOLOGY, EXERCISE TOLERANCE, HEMODYNAMICS AND ECHOCARDIOGRAPHY [J]. CIRCULATION, 1977, 56 (03) : 346 - 354

[7] CLINICAL PHARMACOLOGY AND THERAPEUTIC APPLICATION OF PRAZOSIN IN ACUTE AND CHRONIC REFRACTORY CONGESTIVE HEART-FAILURE - BALANCED SYSTEMIC VENOUS AND ARTERIAL DILATION IMPROVING PULMONARY CONGESTION AND CARDIAC-OUTPUT [J]. AMERICAN JOURNAL OF MEDICINE, 1978, 65 (01) : 146 - 154

[8] PRAZOSIN, PHARMACOKINETICS AND CONCENTRATION EFFECT [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 177 - 181

[9] SIDE-EFFECTS DUE TO TREATMENT OF HYPERTENSION WITH PRAZOSIN [J]. BRITISH MEDICAL JOURNAL, 1975, 2 (5973) : 727 - 728

[10] PHARMACOKINETICS IN PATIENTS WITH CARDIAC-FAILURE [J]. CLINICAL PHARMACOKINETICS, 1976, 1 (06) : 389 - 405

[1] DIFFERENT ALPHA-ADRENORECEPTORS IN CENTRAL NERVOUS-SYSTEM MEDIATING BIOCHEMICAL AND FUNCTIONAL EFFECTS OF CLONIDINE AND RECEPTOR BLOCKING-AGENTS [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1976, 292 (01) : 43 - 52

[2] ANDEN NE, 1978, NAUNYNSCHMIEDEBERGS, V302, P294

[3] ANDERSON MJ, 1979, BRIT J PHARMACOL, V66, pP151

[4] PRAZOSIN IN HYPERTENSION WITH HEART-FAILURE [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1979, 1 (06) : S56 - S62

[5] ALPHA-ADRENERGIC BLOCKING ACTIVITY OF PRAZOSIN - EFFECT ON CATECHOLAMINE LEVELS AND CATECHOLAMINE SYNTHETIC ENZYMES [J]. BIOCHEMICAL PHARMACOLOGY, 1979, 28 (07) : 1233 - 1237

[6] EFFICACY OF AMBULATORY SYSTEMIC VASODILATOR THERAPY WITH ORAL PRAZOSIN IN CHRONIC REFRACTORY HEART-FAILURE - CONCOMITANT RELIEF OF PULMONARY CONGESTION AND ELEVATION OF PUMP OUTPUT DEMONSTRATED BY IMPROVEMENTS IN SYMPTOMATOLOGY, EXERCISE TOLERANCE, HEMODYNAMICS AND ECHOCARDIOGRAPHY [J]. CIRCULATION, 1977, 56 (03) : 346 - 354

[7] CLINICAL PHARMACOLOGY AND THERAPEUTIC APPLICATION OF PRAZOSIN IN ACUTE AND CHRONIC REFRACTORY CONGESTIVE HEART-FAILURE - BALANCED SYSTEMIC VENOUS AND ARTERIAL DILATION IMPROVING PULMONARY CONGESTION AND CARDIAC-OUTPUT [J]. AMERICAN JOURNAL OF MEDICINE, 1978, 65 (01) : 146 - 154

[8] PRAZOSIN, PHARMACOKINETICS AND CONCENTRATION EFFECT [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 16 (03) : 177 - 181

[9] SIDE-EFFECTS DUE TO TREATMENT OF HYPERTENSION WITH PRAZOSIN [J]. BRITISH MEDICAL JOURNAL, 1975, 2 (5973) : 727 - 728

[10] PHARMACOKINETICS IN PATIENTS WITH CARDIAC-FAILURE [J]. CLINICAL PHARMACOKINETICS, 1976, 1 (06) : 389 - 405